Skip to main content
AKBA logo

AKBA · Akebia Therapeutics, Inc. · Metrics

Track AKBA — free
$0.42 +0.01 (+3.28%) At close · Nov 19 Play latest call Q3 2026 earnings call transcript
Market Cap
$117.26M
Shares
277.66M
Volume · Nov 19 2.75M Avg daily vol (3M) 8.17M

AKBA metrics

84 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.42
Market cap
$117.26M

Price action

23 metrics
Price change (1W)
-15.2%
Price change (30D)
-27.8%
Price change (3M)
-54.0%
Price change (6M)
-58.6%
Price change (YTD)
-73.8%
Price change (1Y)
-73.4%
Trailing year
Price change (5Y)
-84.8%
52-week high
$1.70
52-week low
$0.40
Change from 52-week high
-75.2%
Change from 52-week low
+5.5%
Annualized volatility
89.9%
Annualized volatility (3M)
128.6%
Implied volatility (30D)
149.3%
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
2.6
RSI (14D)
34.9
Price vs SMA 50
-41.9%
Price vs SMA 200
-61.1%
Avg volume (3M)
8.17M
Relative volume
0.3
Average dollar volume
$6.30M

Company

3 metrics
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Shares outstanding
277.66M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
0.0×
reciprocal yield 2,383.5%
EV / EBITDA
—
EV / EBIT
—
P / sales
0.6×
reciprocal yield 168.2%
P / book
5.8
reciprocal yield 17.4%
FCF yield
11.8%
TTM · current market cap
Buyback yield
—
P / FCF
8.5
reciprocal yield 11.8%
P / operating cash flow
7.4
reciprocal yield 13.5%
Earnings yield
-38.0%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
1.6×
reciprocal yield 61.1%
EV / revenue historical average (5Y)
1.3×
reciprocal yield 74.9%
EV / EBIT historical average (3Y)
239.9×
reciprocal yield 0.4%
EV / EBIT historical average (5Y)
239.9×
reciprocal yield 0.4%
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-11-05

Profitability

9 metrics
Gross margin
78.9%
Operating margin
-15.7%
Trailing 12 months
Net margin
-22.6%
Gross profit (TTM)
$155.59M
Operating profit (TTM)
−$31.04M
Net income (TTM)
−$44.56M
Trailing 12 months
Diluted EPS (TTM)
$-0.16
FCF margin
7.0%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
$-0.06
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$0.12

Growth

11 metrics
Revenue growth YoY
-37.2%
Year over year
Net income growth YoY
-2,758.1%
Revenue (TTM)
$197.20M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+0.9%
Year over year · more shares
Revenue CAGR (3Y)
-6.9%
Revenue CAGR (5Y)
-4.3%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-218.8%
Return on assets
-13.0%
Debt / equity
2.5
Current ratio
1.4
EBITDA (TTM)
—
Free cash flow (TTM)
$13.86M
Quick ratio
1.2
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$108.98M
Latest balance sheet
Cash & equivalents
$159.25M
Total assets
$342.13M
Total debt
$50.27M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$15.78M
Capital expenditures (TTM)
$1.92M
R&D (TTM)
$71.70M
SG&A (TTM)
$108.23M
Stock compensation (TTM)
$12.89M
R&D / revenue
36.4%
Stock compensation / revenue
6.5%

Ownership (13F)

9 metrics
13F filers
157
13F filer change QoQ
-13
Institutional ownership
39.2%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
10.2%
Private-fund adviser ownership
10.1%
Active holders' share change QoQ
+0.2%
Holder tenure
11.7
Price vs estimated holder cost
-42.1%

Ownership (registered funds)

1 metrics
Index-fund ownership
13.1%

Short interest

3 metrics
Short interest
9.8%
Latest settlement · 3.0 days to cover
Days to cover
3.0d
Short-squeeze score
62 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1517022 CUSIP 00972D105 13F (30d) 157 filings 140 filers Visit website Investor relations